Novanta (NOVT) Earnings Date & Reports

Key Takeaways

• Novanta (NOVT) is scheduled to report second quarter 2026 results after U.S. markets close on Wednesday, August 5, 2026, with a conference call to follow on Thursday, August 6, at 8:00 a.m. ET.
• Company-issued Q2 guidance calls for adjusted earnings per share (EPS) of $0.81 to $0.86 on revenue of $259 million to $264 million, implying organic revenue growth of 6% to 8% year-over-year.
• Wall Street consensus estimates vary across sources, with EPS expectations ranging from $0.82 to $0.85 and revenue estimates between $257 million and $268 million, reflecting a modest dispersion among analysts.
• Novanta enters this earnings event with strong momentum from Q1 2026, when it delivered a 37% surge in bookings, a book-to-bill ratio of 1.10, and both top- and bottom-line beats.
• Tariff-related cost pressures and recent stock price weakness add an element of uncertainty heading into the print, with shares pulling back roughly 15% from their early July peak.
• Full-year 2026 guidance was raised following Q1 results, with management targeting revenue of $1.04 billion to $1.055 billion and adjusted EPS of $3.50 to $3.65.

Earnings Context and Why It Matters

Novanta's second quarter report lands at a pivotal moment for the precision technology company. With its portfolio now weighted over 50% toward medical applications — following the accretive acquisition of Riverpoint Medical — Novanta has been reshaping its revenue mix toward higher-growth, recurring surgical consumables while reducing exposure to cyclical semiconductor markets. The Q2 print will test whether this strategic pivot continues to pay off in an environment marked by tariff uncertainty and uneven industrial demand. For investors, the report serves as a temperature check on medical technology capital spending, robotics and automation adoption, and management's ability to sustain the margin expansion story that gained traction in the first quarter.

Earnings Expectations

Novanta's own Q2 2026 guidance, issued alongside its Q1 release on May 11, sets adjusted EPS in a range of $0.81 to $0.86 on revenue of $259 million to $264 million. At the midpoint, that implies approximately 10% reported revenue growth and roughly 7% to 13% adjusted EPS growth compared with Q2 2025, when the company posted EPS of $0.76 on revenue of $241 million. On the consensus front, estimates from tracked analysts show some variation: Nasdaq and Zacks report a consensus EPS of $0.82 based on two analysts, while broader consensus figures compiled by other data providers range from $0.83 to $0.85 per share, with revenue estimates spanning $257 million to roughly $268 million. The company's guidance midpoint sits comfortably within or slightly below the higher end of the analyst range, suggesting that expectations are well-anchored but not aggressively stretched.

Key operating metrics under scrutiny will include organic revenue growth (targeted at 6% to 8%), adjusted gross margin (guided to approximately 45.5% to 46%), and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), which management pegged at $58 million to $62 million for the quarter. Investors will also watch for updates on the book-to-bill ratio, which stood at a healthy 1.10 in Q1, signaling that order intake outpaced shipments and supporting the case for continued demand momentum.

AI Screener

As earnings season intensifies, investors looking to cut through the noise may find value in Tickeron's AI Screener, an AI-powered stock and exchange-traded fund (ETF) discovery platform designed to help traders and investors filter thousands of equities using customizable criteria. The screener enables users to scan by industry, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven trading signals, making it possible to surface breakout candidates, trend-following setups, and undervalued opportunities far more efficiently than manual screening. For those tracking Novanta and its medical technology peers, the AI Screener offers a practical way to monitor shifting sector dynamics and identify actionable trade ideas as earnings reports roll out.

Market Reaction and Investor Sentiment

Novanta shares have experienced a notable pullback heading into the Q2 report, declining from a July 6 intraday high of $166.75 to approximately $140.80 as of July 27 — a drop of roughly 15% in under three weeks. The sell-off coincided with a wave of insider selling disclosed on July 7, as well as broader market rotation away from mid-cap growth names. Despite the near-term pressure, the stock remains up approximately 19% year-to-date and is still trading well above its 52-week low of $98.27. Analyst sentiment remains broadly constructive, with three analysts tracked by major platforms rating the stock a consensus "Strong Buy" and assigning a 12-month average price target of $175, implying over 24% upside from current levels. Heading into the August 5 release, investor sentiment appears cautiously optimistic: Q1's double-digit bookings growth and raised full-year guidance provide a favorable setup, but tariff-related input cost headwinds and foreign exchange fluctuations represent known risks that could pressure margins in the near term.

Forward Outlook and Key Factors to Monitor

Beyond the headline Q2 numbers, several forward-looking themes will command investor attention during the conference call and in the weeks that follow.

First, tariff mitigation and pricing actions will be a central focus. Management has previously outlined surcharges, customer price increases, and planned site consolidations as levers to restore gross margins in the second half of 2026. Any update on the timeline and magnitude of these initiatives will be closely scrutinized, particularly given that tariff-related cost headwinds created an estimated $0.03 EPS drag in the first quarter.

Second, the integration of Riverpoint Medical and the broader push into surgical consumables remain key growth catalysts. Investors will want to hear about revenue synergy progress, cross-selling traction with existing original equipment manufacturer (OEM) relationships, and whether the acquisition continues to track ahead of initial accretion expectations.

Third, demand signals across Novanta's end markets — particularly medical and life sciences, robotics and automation, and precision manufacturing — will provide important read-throughs for the balance of the year. With full-year guidance already raised, the market will be watching for any additional upward revision or, conversely, any signs of caution that could temper second-half expectations.

Finally, capital allocation strategy, including the strength of Novanta's merger and acquisition (M&A) pipeline and cash flow conversion (which exceeded 200% in Q1), will shape the investment narrative heading into the final months of fiscal 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations